{
    "name": "tetanus & reduced diphtheria toxoids/ acellular pertussis vaccine",
    "comment": "Rx",
    "other_names": [
        "Adacel",
        "Boostrix",
        "Tdap"
    ],
    "classes": [
        "Vaccines",
        "Combos"
    ],
    "source": "https://reference.medscape.com/drug/adacel-boostrix-tetanus-reduced-diphtheria-toxoids-acellular-pertussis-vaccine-999568",
    "pregnancy": {
        "common": [
            "There are no adequate and well-controlled studies of administration in pregnant women",
            "Available data suggest the rates of major birth defects and miscarriage in women who receive Tdap within 30 days prior to pregnancy or during pregnancy are consistent with estimated background rates"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "Adacel: Two developmental toxicity studies were performed in female rabbits given 0.5 mL (a single human dose) of Adacel twice prior and during gestation",
                    "Boostrix: Developmental toxicity studies were performed in female rats and New Zealand White rabbits did not observe fetal abnormalities following vaccine administration before mating and during gestation"
                ]
            },
            {
                "type": "Pregnancy registries",
                "description": [
                    "Clinicians are encouraged to call and register women in the following pregnancy exposure registries",
                    "Adacel: 1-800-822- 2463 (1-800-VACCINE)",
                    "Boostrix: 1-888-452-9622"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Unknown if distributed in human breast milk",
            "Consider the developmental and health benefits of breastfeeding along with the motherâ€™s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "elivaldogene autotemcel",
            "description": {
                "common": "elivaldogene autotemcel, tetanus & reduced diphtheria toxoids/ acellular pertussis vaccine.\nEither decreases effects of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: The safety and effectiveness of vaccination during or following elivaldogene autotemcel treatment have not been studied. Vaccination is not recommended during the 6 weeks preceding myeloablative conditioning, and until hematological recovery following elivaldogene autotemcel treatment. Where feasible, administer childhood vaccinations before myeloablative conditioning. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ixekizumab",
            "description": {
                "common": "ixekizumab decreases effects of tetanus & reduced diphtheria toxoids/ acellular pertussis vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Prior to initiating ixekizumab, complete all age appropriate immunizations; non-live vaccinations received during treatment with ixekizumab may not elicit an immune response sufficient to prevent disease."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "secukinumab",
            "description": {
                "common": "secukinumab decreases effects of tetanus & reduced diphtheria toxoids/ acellular pertussis vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Prior to initiating secukinumab, complete all age appropriate immunizations; non-live vaccinations received during treatment with secukinumab may not elicit an immune response sufficient to prevent disease."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod decreases effects of tetanus & reduced diphtheria toxoids/ acellular pertussis vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Pause vaccinations beginning 1 week before initiating siponimod and for 4 weeks after stopping treatment. Coadministration with live attenuated vaccines may increase infection risk."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "teplizumab",
            "description": {
                "common": "teplizumab decreases effects of tetanus & reduced diphtheria toxoids/ acellular pertussis vaccine by Other (see comment). Avoid or Use Alternate Drug. \nComment: Administer all age-appropriate vaccinations before starting teplizumab. Inactivated or mRNA vaccines are not recommended within 2 weeks before teplizumab treatment, during treatment, or 6 weeks after completion of treatment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "certolizumab pegol",
            "description": {
                "common": "certolizumab pegol decreases effects of tetanus & reduced diphtheria toxoids/ acellular pertussis vaccine by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "ifosfamide decreases effects of tetanus & reduced diphtheria toxoids/ acellular pertussis vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "melphalan",
            "description": {
                "common": "melphalan decreases effects of tetanus & reduced diphtheria toxoids/ acellular pertussis vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "oxaliplatin decreases effects of tetanus & reduced diphtheria toxoids/ acellular pertussis vaccine by passive renal tubular reabsorption due to increased pH. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab decreases effects of tetanus & reduced diphtheria toxoids/ acellular pertussis vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Administer all immunizations according to immunization guidelines at least 4 weeks before initiating ublituximab for live or live-attenuated vaccines and, whenever possible, at least 2 weeks before initiating for non-live vaccines. Vaccination with live virus vaccines is not recommended during treatment and until B-cell repletion. Do not administer live or live-attenuated vaccines to infants of mothers exposed to ublituximab during pregnancy, before confirming recovery of B-cell counts as measured by CD19+ B cells."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Pain",
            "percent": "21.5"
        },
        {
            "name": "Fatigue",
            "percent": "12.5"
        },
        {
            "name": "Headache",
            "percent": "11.5"
        },
        {
            "name": "Redness",
            "percent": "10.8"
        },
        {
            "name": "Swelling",
            "percent": "7.5"
        },
        {
            "name": "Any injection site pain",
            "percent": "65.7-77.8"
        },
        {
            "name": "Malaise",
            "percent": "30.8-33.3"
        },
        {
            "name": "Headache",
            "percent": "33.9-43.7"
        },
        {
            "name": "Body ache or muscle weakness",
            "percent": "21.9-30.4"
        },
        {
            "name": "Tiredness",
            "percent": "24.3-30.2"
        },
        {
            "name": "Any injection site erythema",
            "percent": "20.8-24.7"
        },
        {
            "name": "Any injection site swelling",
            "percent": "20.9-21"
        },
        {
            "name": "Moderate injection site pain",
            "percent": "15.1-18"
        },
        {
            "name": "Chills",
            "percent": "8.1-15.1"
        },
        {
            "name": "Nausea",
            "percent": "9.2-13.3"
        },
        {
            "name": "Sore and swollen joints",
            "percent": "9.1-11.3"
        },
        {
            "name": "Diarrhea",
            "percent": "10.3"
        },
        {
            "name": "Gastrointestinal symptoms",
            "percent": "7.6"
        },
        {
            "name": "Swelling",
            "percent": "7.5"
        },
        {
            "name": "Fever",
            "percent": "99.5"
        },
        {
            "name": "F",
            "percent": "37.5"
        },
        {
            "name": "C",
            "percent": "1.2-8.5"
        },
        {
            "name": "Body aches",
            "percent": "2.7-8.4"
        },
        {
            "name": "muscle weakness",
            "percent": "6.5-6.6"
        },
        {
            "name": "Injection site erythema",
            "percent": "2.8-6.4"
        },
        {
            "name": "Lymph node swelling",
            "percent": "1.4-5"
        },
        {
            "name": "Injection site swelling",
            "percent": "3-4.6"
        },
        {
            "name": "Fever",
            "percent": "1.3-3.2"
        },
        {
            "name": "Vomiting",
            "percent": "1-3.2"
        },
        {
            "name": "Chills",
            "percent": "2-2.7"
        },
        {
            "name": "moderate",
            "percent": "2.5"
        },
        {
            "name": "Nausea",
            "percent": "1.1-1.5"
        },
        {
            "name": "Rash",
            "percent": "1"
        },
        {
            "name": "Joint pain",
            "percent": null
        },
        {
            "name": "moderate",
            "percent": null
        },
        {
            "name": "Severe injection site reactions",
            "percent": null
        },
        {
            "name": "Lymphadenopathy",
            "percent": null
        }
    ]
}